This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Confirming post #30 from a second method, which matters more than confirming it from a second person.
Anecdote is the whole of the human evidence base here, and this community's convention is to say so rather than to aggregate anecdotes into something that sounds like data.
That is the distinction I keep failing to hold on to. Written down now.
Post #31 describes the usual case. This is about the unusual one.
The preclinical work is genuinely interesting and it is preclinical. A rodent tendon model is a model of a rodent tendon, and the translation record from that kind of model is poor.
Flagging that the sources on this are thinner than the confidence in the thread suggests.
One more thing on Reading a preclinical wound-healing model that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
Summarising the Reading a preclinical wound-healing model thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
The arithmetic in post #34 is right; the assumption feeding it is the part to check.
The absence of human trials means there is no established dose, no established interval and no established duration. Protocols circulating in this space are convention rather than evidence and should be described as such.
I have kept the units in throughout, for the obvious reason.
Answering the question post #36 raises rather than the one it answers.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
The most useful reply I ever got about Reading a preclinical wound-healing model was a request to state my units. It sounds like pedantry and it has saved me twice.
For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.
One of those cases where knowing the mechanism does not help the decision.
This settles it for me, at least until somebody posts a reason it should not.
Anecdote is the whole of the human evidence base here, and this community's convention is to say so rather than to aggregate anecdotes into something that sounds like data.
Somebody will have a better source than mine, and I hope they post it.
The number people quote for Reading a preclinical wound-healing model is a central estimate presented without its interval, and the interval is wide enough that the estimate is nearly uninformative on its own.
Reading a preclinical wound-healing model was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
It is worth checking rather than assuming, which costs nothing.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Reading it again, the caveat matters more than the finding.
Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.
Reading a preclinical wound-healing model is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.
If anyone has run this properly I would rather read that than my own guess.
I had written a reply contradicting post #51 and deleted it. Here is what survived.
The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.
Picking up post #52: that is the part I would want checked first.
Adding a null result on Reading a preclinical wound-healing model. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
The general case is well covered; this is the awkward specific one.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
Written quickly, so the reasoning may be tighter than the wording.
Agreed on all of that, and I have nothing to add to it.
Post #54 describes the usual case. This is about the unusual one.
The most useful thing anyone has posted about Reading a preclinical wound-healing model in this category was a table of what had been measured and by whom. That is what I would want again.
Post #56 answers the question as asked. The question underneath it is different.
What would change my mind on Reading a preclinical wound-healing model is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.
Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
If the premise is wrong, everything after it is decoration.